![Patrick Yeramian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Yeramian
Corporate Officer/Principal bij
Dlx Therapeutics L L C
Profiel
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Actieve functies van Patrick Yeramian
| Bedrijven | Functie | Begin |
|---|---|---|
Dlx Therapeutics L L C | Corporate Officer/Principal | 01-01-2018 |
Eerdere bekende functies van Patrick Yeramian
| Bedrijven | Functie | Einde |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 28-11-2023 |
| BIOVIE INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Hoofd Techniek/Wetenschap/O&O | 01-03-2019 |
| MARKER THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 |
Tapimmune, Inc. | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 |
Opleiding van Patrick Yeramian
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
15
Eerstegraads connecties
13
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 13 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Develops and researches immunological products | Health Technology |
Marker Therapeutics, Inc.
 Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universite Paris Est Creteil Val De Marne
 Universite Paris Est Creteil Val De Marne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
G.D. Searle LLC | |
Rutgers Business School
 Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
Amylyx Pharmaceuticals, Inc.
 Amylyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products to cure neurodegenerative diseases | Health Technology |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Commercial Services |
Dlx Therapeutics L L C | |
Tapimmune, Inc. |
